BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
77 results:

  • 1. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
    Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
    Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
    Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
    Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Epigenetic MLH1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
    Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
    J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
    Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
    Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
    Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
    Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Constitutional Mismatch Repair Deficiency Syndrome as a Cause of Numerous Malignancies in a Teenage Patient-A Case Report.
    Samborska M; Galli D; Achkar R; Thambyrajah S; Derwich K
    J Pediatr Hematol Oncol; 2023 Oct; 45(7):e917-e920. PubMed ID: 37526375
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
    Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
    Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.
    Benusiglio PR; Elder F; Touat M; Perrier A; Sanson M; Colas C; Guerrini-Rousseau L; Tran DT; Trabelsi N; Carpentier C; Marie Y; Adam C; Bernier M; Cazals-Hatem D; Mokhtari K; Tran S; Mathon B; Capelle L; Dhooge M; Idbaih A; Alentorn A; Houillier C; Dehais C; Hoang-Xuan K; Cuzzubbo S; Carpentier A; Duval A; Coulet F; Bielle F
    JCO Precis Oncol; 2023 May; 7():e2200525. PubMed ID: 37262394
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
    Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
    Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Temozolomide treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal cancer Patients.
    Crisafulli G; Sartore-Bianchi A; Lazzari L; Pietrantonio F; Amatu A; Macagno M; Barault L; Cassingena A; Bartolini A; Luraghi P; Mauri G; Battuello P; Personeni N; Zampino MG; Pessei V; Vitiello PP; Tosi F; Idotta L; Morano F; Valtorta E; Bonoldi E; Germano G; Di Nicolantonio F; Marsoni S; Siena S; Bardelli A
    Cancer Discov; 2022 Jul; 12(7):1656-1675. PubMed ID: 35522273
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Mismatch repair deficiency and MUTYH variants in small intestine-neuroendocrine tumors.
    Helderman NC; Elsayed FA; van Wezel T; Terlouw D; Langers AMJ; van Egmond D; Kilinç G; Hristova H; Farina Sarasqueta A; Morreau H; Nielsen M; Suerink M;
    Hum Pathol; 2022 Jul; 125():11-17. PubMed ID: 35417733
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
    Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
    Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Kolaviron, a flavonoid-rich extract ameliorates busulfan-induced chemo-brain and testicular damage in male rats through inhibition of oxidative stress, inflammatory, and apoptotic pathways.
    Tesi EP; Ben-Azu B; Mega OO; Mordi J; Knowledge OO; Awele ED; Rotu RA; Emojevwe V; Adebayo OG; Eneni OA
    J Food Biochem; 2022 Apr; 46(4):e14071. PubMed ID: 35060131
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
    AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
    Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Sporadic and Lynch syndrome-associated mismatch repair-deficient brain tumors.
    Kim H; Lim KY; Park JW; Kang J; Won JK; Lee K; Shim Y; Park CK; Kim SK; Choi SH; Kim TM; Yun H; Park SH
    Lab Invest; 2022 Feb; 102(2):160-171. PubMed ID: 34848827
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Intensive surveillance endoscopy for multiple gastrointestinal tumors in a patient with constitutional mismatch repair deficiency: case report.
    Ando T; Nakajima T; Fukuda R; Nomura K; Niida Y; Sakumura M; Motoo I; Mihara H; Nanjo S; Kajiura S; Fujinami H; Hojo S; Fujii T; Yasuda I
    BMC Gastroenterol; 2021 Aug; 21(1):326. PubMed ID: 34425783
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
    Alphones S; Chatterjee U; Singh A; Das A; Zameer L; Achari R; Bhattacharya A; Roy P
    Childs Nerv Syst; 2021 Aug; 37(8):2521-2530. PubMed ID: 34097097
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in brain Malignancies from Young Individuals.
    Carrato C; Sanz C; Muñoz-Mármol AM; Blanco I; Pineda M; Del Valle J; Dámaso E; Esteller M; Musulen E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33924881
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival - an immunohistochemical study.
    Melincovici CS; Boşca AB; Şuşman S; Cutaş A; Mărginean M; Ilea A; Moldovan IM; Jianu EM; Neag MA; Bulboacă AE; Mihu CM
    Rom J Morphol Embryol; 2020; 61(3):715-727. PubMed ID: 33817713
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.